BACKGROUND: Coinciding with the relatively good and improving prognosis for patients with stage I-III breast cancer, late recurrences, new primary tumours and late side-effects of treatment may occur. We gained insight into prognosis for long-term breast cancer survivors. PATIENTS AND METHODS: Data on all 205 827 females aged 15-89 diagnosed with stage I-III breast cancer during 1989-2008 were derived from the Netherlands Cancer Registry. Conditional 5-year relative survival was calculated for every subsequent year from diagnosis up to 15 years. RESULTS: For stage I, conditional 5-year relative survival remained ~95% up to 15 years after diagnosis (a stable 5-year excess mortality rate of 5%). For stage II, excess mortality remained 10% for those aged 15-44 or 45-59 and 15% for those aged 60-74. For stage III, excess mortality decreased from 35% at diagnosis to 10% at 15 years for those aged 15-44 or 45-59, and from ~40% to 30% for those aged ≥60. CONCLUSIONS: Patients with stage I or II breast cancer had a (very) good long-term prognosis, albeit exhibiting a small but significant excess mortality at least up to 15 years after diagnosis. Improvements albeit from a lower level were mainly seen for patients who had been diagnosed with stage III disease. Caregivers can use this information to better inform (especially disease-free) cancer survivors about their actual prognosis.
BACKGROUND: Coinciding with the relatively good and improving prognosis for patients with stage I-III breast cancer, late recurrences, new primary tumours and late side-effects of treatment may occur. We gained insight into prognosis for long-term breast cancer survivors. PATIENTS AND METHODS: Data on all 205 827 females aged 15-89 diagnosed with stage I-III breast cancer during 1989-2008 were derived from the Netherlands Cancer Registry. Conditional 5-year relative survival was calculated for every subsequent year from diagnosis up to 15 years. RESULTS: For stage I, conditional 5-year relative survival remained ~95% up to 15 years after diagnosis (a stable 5-year excess mortality rate of 5%). For stage II, excess mortality remained 10% for those aged 15-44 or 45-59 and 15% for those aged 60-74. For stage III, excess mortality decreased from 35% at diagnosis to 10% at 15 years for those aged 15-44 or 45-59, and from ~40% to 30% for those aged ≥60. CONCLUSIONS:Patients with stage I or II breast cancer had a (very) good long-term prognosis, albeit exhibiting a small but significant excess mortality at least up to 15 years after diagnosis. Improvements albeit from a lower level were mainly seen for patients who had been diagnosed with stage III disease. Caregivers can use this information to better inform (especially disease-free) cancer survivors about their actual prognosis.
Entities:
Keywords:
breast cancer; conditional survival; excess mortality; late side-effects; long-term survivors
Authors: L Dal Maso; S Guzzinati; C Buzzoni; R Capocaccia; D Serraino; A Caldarella; A P Dei Tos; F Falcini; M Autelitano; G Masanotti; S Ferretti; F Tisano; U Tirelli; E Crocetti; R De Angelis; S Virdone; A Zucchetto; A Gigli; S Francisci; P Baili; G Gatta; M Castaing; R Zanetti; P Contiero; E Bidoli; M Vercelli; M Michiara; M Federico; G Senatore; F Pannozzo; M Vicentini; A Bulatko; D R Pirino; M Gentilini; M Fusco; A Giacomin; A C Fanetti; R Cusimano Journal: Ann Oncol Date: 2014-08-22 Impact factor: 32.976
Authors: R Clèries; A Ameijide; M Buxó; J M Martínez; R Marcos-Gragera; M-L Vilardell; M Carulla; Y Yasui; M Vilardell; J A Espinàs; J M Borràs; J Galceran; À Izquierdo Journal: Clin Transl Oncol Date: 2018-03-06 Impact factor: 3.405
Authors: Marissa C van Maaren; Robert F Kneepkens; Joke Verbaan; Peter C Huijgens; Valery E P P Lemmens; Rob H A Verhoeven; Sabine Siesling Journal: PLoS One Date: 2019-01-24 Impact factor: 3.240
Authors: Luigino Dal Maso; Chiara Panato; Stefano Guzzinati; Diego Serraino; Silvia Francisci; Laura Botta; Riccardo Capocaccia; Andrea Tavilla; Anna Gigli; Emanuele Crocetti; Massimo Rugge; Giovanna Tagliabue; Rosa Angela Filiberti; Giuliano Carrozzi; Maria Michiara; Stefano Ferretti; Rosaria Cesaraccio; Rosario Tumino; Fabio Falcini; Fabrizio Stracci; Antonietta Torrisi; Guido Mazzoleni; Mario Fusco; Stefano Rosso; Francesco Tisano; Anna Clara Fanetti; Giovanna Maria Sini; Carlotta Buzzoni; Roberta De Angelis Journal: Cancer Med Date: 2019-06-17 Impact factor: 4.452
Authors: K M de Ligt; M Heins; J Verloop; N P M Ezendam; C H Smorenburg; J C Korevaar; S Siesling Journal: Breast Cancer Res Treat Date: 2019-09-11 Impact factor: 4.872
Authors: Marissa C van Maaren; Bernard Rachet; Gabe S Sonke; Audrey Mauguen; Virginie Rondeau; Sabine Siesling; Aurélien Belot Journal: Cancer Epidemiol Date: 2022-02-05 Impact factor: 2.890
Authors: Kelly M de Ligt; Laurentine S E van Egdom; Linetta B Koppert; Sabine Siesling; Janine A van Til Journal: Eur J Cancer Care (Engl) Date: 2019-05-09 Impact factor: 2.328